-
-
-
-
-
-
-
Takeda psoriasis drug shows skin clearance in Phase 3 trials
-
-
-
-
-
-
-
U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
-
-
-
-
-
-
-
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
-
-
-
-
-
-
-
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
-
-
-
-
-
-
-
Takeda partners with Innovent for $1.2 billion oncology deal
-
-
-
-
-
-
-
Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025
-
-
-
-
-
-
-
Takeda Announces New Assignments of Directors
-
1,185,268 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

